Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : To Acquire Privately Held Teneobio for $900 Million In Cash

07/27/2021 | 05:49pm EDT


© MT Newswires 2021
All news about AMGEN INC.
09/16AMGEN : Diversity, Inclusion and Belonging at Amgen – A Progress Report
PU
09/16AMGEN : Enters Collaboration With Boehringer Ingelheim to Study Drug Combination..
MT
09/16AMGEN : Conference Call from ESMO Presentation
PU
09/16AMGEN : Says Colorectal Cancer Drug Combination Safe and Effective in Trial
MT
09/16AMGEN : LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed..
PR
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/14AMGEN : And The Lundquist Institute Announce That Diadem Therapeuctics Will Rece..
PR
09/14INSIDER BUY : Beigene
MT
09/14Health Canada Approves Amgen's LUMAKRAS™, the First and Only Targeted Treatme..
CI
09/13AMGEN : To Present At The 2021 Bank of America Merrill Lynch Global Healthcare C..
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 045 M - -
Net income 2021 6 027 M - -
Net Debt 2021 22 255 M - -
P/E ratio 2021 20,4x
Yield 2021 3,19%
Capitalization 123 B 123 B -
EV / Sales 2021 5,59x
EV / Sales 2022 5,26x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 217,36 $
Average target price 245,81 $
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-5.46%123 428
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456